Home > Publications Database > Copathology in Progressive Supranuclear Palsy: Does It Matter? > print

001     153339
005     20240321221041.0
024 7 _ |a 10.1002/mds.28011
|2 doi
024 7 _ |a pmid:32125724
|2 pmid
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:77018928
|2 altmetric
037 _ _ |a DZNE-2020-01336
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Jecmenica Lukic, Milica
|0 P:(DE-2719)2812616
|b 0
|u dzne
245 _ _ |a Copathology in Progressive Supranuclear Palsy: Does It Matter?
260 _ _ |a New York, NY
|c 2020
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1605802412_430
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The influence of concomitant brain pathologies on the progression rate in PSP is unclear.To analyze the frequency and severity of copathologies and their impact on the progression in PSP.We analyzed clinic-pathological features of 101 PSP patients. Diagnoses and stages of copathologies were established according to standardized criteria, including Alzheimer's disease-related pathology, argyrophilic grains, Lewy-related pathology, transactive response DNA-binding protein 43 pathology, fused in sarcoma pathology, cerebral amyloid angiopathy, and small vessel disease. Demographic data and major clinical milestones (frequency and latency to onset) were extracted from patients' files.Only 8% of 101 patients presented with pure PSP pathology without any copathology. Alzheimer's disease-related pathology was the most frequent (84%), followed by argyrophilic grains (58%), both occurring as single copathology or in combination with other proteinopathies or cerebrovascular disease. Lewy-related and transactive response DNA-binding protein 43 copathology occurred rarely (8% and 6%, respectively). Fused in sarcoma-positive cases were not found. While being common, copathology was mostly mild in severity, with the exception of frequently widespread argyrophilic grains. Small vessel disease was also frequent (65%). Cerebral amyloid angiopathy occurred only in the presence of Alzheimer's disease-related changes (25%). The copathologies did not have major impact on prevalence and time frame of major disease milestones.In PSP, concomitant neurodegenerative proteinopathies or cerebrovascular diseases are frequent, but generally mild in severity. Our data confirmed that four repeat tau is still the most relevant target for PSP, whereas the impact of copathologies on progression rate appears to be of less importance. This is relevant information for the development of disease-modifying therapies. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Alzheimer Disease: epidemiology
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Movement Disorders
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: epidemiology
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
700 1 _ |a Kurz, Carolin
|0 P:(DE-2719)9000176
|b 1
|u dzne
700 1 _ |a Respondek, Gesine
|0 P:(DE-2719)2811600
|b 2
|u dzne
700 1 _ |a Grau-Rivera, Oriol
|b 3
700 1 _ |a Compta, Yaroslau
|b 4
700 1 _ |a Gelpi, Ellen
|b 5
700 1 _ |a Troakes, Claire
|b 6
700 1 _ |a Barcelona Brain Bank collaborative group, the MDS-endorsed PSP study group
|0 P:(DE-HGF)0
|b 7
700 1 _ |a van Swieten, John C
|b 8
700 1 _ |a Giese, Armin
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Roeber, Sigrun
|b 10
700 1 _ |a Arzberger, Thomas
|0 P:(DE-2719)2811333
|b 11
|u dzne
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 12
|e Last author
|u dzne
700 1 _ |a Grau-Rivera, O.
|b 13
700 1 _ |a Compta, Y.
|b 14
700 1 _ |a Tolosa, E.
|b 15
700 1 _ |a Martí, M. J.
|b 16
700 1 _ |a Valldeoriola, F.
|b 17
700 1 _ |a Pagonabarraga, J.
|b 18
700 1 _ |a Calopa, M.
|b 19
700 1 _ |a Bayès, A.
|b 20
700 1 _ |a Hernandez, I.
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Aguilar, M.
|b 22
700 1 _ |a Genis, D.
|b 23
700 1 _ |a Fernandez, M.
|b 24
700 1 _ |a Munoz-Garcia, C.
|b 25
700 1 _ |a Antonell, A.
|b 26
700 1 _ |a Gelpi, E.
|b 27
773 _ _ |a 10.1002/mds.28011
|g Vol. 35, no. 6, p. 984 - 993
|0 PERI:(DE-600)2041249-6
|n 6
|p 984 - 993
|t Movement disorders
|v 35
|y 2020
|x 1531-8257
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/153339/files/mds.28011.pdf
856 4 _ |y OpenAccess
|x icon
|u https://pub.dzne.de/record/153339/files/mds.28011.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://pub.dzne.de/record/153339/files/mds.28011.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://pub.dzne.de/record/153339/files/mds.28011.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://pub.dzne.de/record/153339/files/mds.28011.jpg?subformat=icon-640
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/153339/files/mds.28011.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:153339
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812616
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000176
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811600
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811333
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|2 G:(DE-HGF)POF3-300
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2020-08-32
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-32
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1111015
|k AG Höglinger 2
|l Coordinator of Clinical Parkinson Research
|x 0
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger 1
|l Translational Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)6000016
|k München Pre 2020
|l München Pre 2020
|x 2
920 1 _ |0 I:(DE-2719)1140013
|k Neuropathology / Brainbank
|l Neuropathology / Brainbank
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)6000016
980 _ _ |a I:(DE-2719)1140013
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21